Brief: Edgewise Therapeutics Announces Sale Of Sevasemten To Servier For Up To $2.65 Bln
BRIEF-Edgewise Therapeutics Announces Sale Of Sevasemten To Servier For Up To $2.65 Bln June 1 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE THERAPEUTICS: ANNOUNCES SALE OF SEVASEMTEN TO SERVIER FOR UP TO $2.65 BILLION
EDGEWISE THERAPEUTICS: TO RECEIVE $1.55 BILLION IN UPFRONT CASH CONSIDERATION ELIGIBLE FOR UP TO $1.1 BILLION IN MILESTONE PAYMENTS
EDGEWISE THERAPEUTICS: EMPLOYEES IN MUSCULAR DYSTROPHY BUSINESS TO RECEIVE COMPARABLE OFFERS FROM SERVIER
EDGEWISE THERAPEUTICS: PROCEEDS EXPECTED TO FULLY FUND EDG-7500 DEVELOPMENT THROUGH POTENTIAL APPROVAL
EDGEWISE THERAPEUTICS: REMAINS ON TRACK TO INITIATE PHASE 2 TRIAL OF EDG-15400 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
EDGEWISE THERAPEUTICS: ON TRACK TO REPORT 12-WEEK CIRRUS-HCM PART D DATA IN Q2 2026
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending